Ben Ho Park

Vanderbilt-Ingram Cancer Center earns NCI Merit Award

Vanderbilt-Ingram Cancer Center has earned a Merit Extension Award from the National Cancer Institute in recognition of more than a decade of sustained exceptional progress.

Houra Merrikh and Juan Carvajal-Garcia, PhD, are studying how to prevent cancer therapy resistance. (photo by Erin O. Smith)

Foundation funds research to block drug resistance in cancer treatment

The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance.

Liquid biopsy test may detect early-stage and low DNA-shedding cancers

Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.

Cell-free breast cancer “biopsy”

The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.

Park named director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.

Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).